OncoTartis
Buffalo
About OncoTartis
OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.0M
- Last round: Series Unknown (Dec 2017)
- Website: oncotartis.com
- Phone: 716.858.3055
Industries & Categories
Biometrics, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/oncotartis-11 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.